PureTech Health plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PureTech Health plc
EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director.
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
- Medical Devices
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Vedanta Biosciences, Inc.
- Alivio Therapeutics, Inc.
- resTORbio, Inc.
- Tal Medical
- Vor Biopharma